Format

Send to

Choose Destination
ACS Chem Biol. 2015 Mar 20;10(3):667-74. doi: 10.1021/cb500796d. Epub 2015 Jan 15.

Structure-guided DOT1L probe optimization by label-free ligand displacement.

Author information

1
†Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
2
‡Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
3
§Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States.
4
∥Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
5
⊥Human Oncology and Pathogenesis Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
6
#Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States.
7
○Shanghai ChemPartner Co. Ltd., 998 Hailei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, 201203, China.
8
▽Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.

Abstract

The DOT1L lysine methyltransferase has emerged as a validated therapeutic target in MLL-rearranged (MLLr) acute leukemias. Although S-adenosylmethionine competitive inhibitors have demonstrated pharmacological proof-of-principle in MLLr-leukemia, these compounds require further optimization to improve cellular potency and pharmacokinetic stability. Limiting DOT1L inhibitor discovery and ligand optimization have been complex biochemical methods often using radionucleotides and cellular methods requiring prolonged culture. We therefore developed a new suite of assay technologies that allows comparative assessment of chemical tools for DOT1L in a miniaturized format. Coupling these assays with structural information, we developed new insights into DOT1L ligand binding and identified several functionalized probes with increased cellular potency (IC50 values ∼10 nM) and excellent selectivity for DOT1L. Together these assay technologies define a platform capability for discovery and optimization of small-molecule DOT1L inhibitors.

PMID:
25397901
PMCID:
PMC4504433
DOI:
10.1021/cb500796d
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center